The DOI matches its Crossref record; 28 of the 29 references it cites were found in a registry or an index.
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Open accessAbstract
BACKGROUND: Patients with diffuse large B-cell lymphoma that is refractory to primary and second-line therapies or that has relapsed after stem-cell transplantation have a poor prognosis. The chimeric antigen receptor (CAR) T-cell therapy tisagenlecleucel targets and eliminates CD19-expressing B cells and showed efficacy against B-cell lymphomas in a single-center, phase 2a study. METHODS: We conducted an international, phase 2, pivotal study of centrally manufactured tisagenlecleucel involving adult patients with relapsed or refractory diffuse large B-cell lymphoma who were ineligible for or had disease progression after autologous hematopoietic stem-cell transplantation. The primary end point was the best overall response rate (i.e., the percentage of patients who had a complete or partial response), as judged by an independent review committee. RESULTS: A total of 93 patients received an infusion and were included in the evaluation of efficacy. The median time from infusion to data cutoff was 14 months (range, 0.1 to 26). The best overall response rate was 52% (95% confidence interval, 41 to 62); 40% of the patients had complete responses, and 12% had partial responses. Response rates were consistent across prognostic subgroups. At 12 months after the initial response, the rate of relapse-free survival was estimated to be 65% (79% among patients with a complete response). The most common grade 3 or 4 adverse events of special interest included cytokine release syndrome (22%), neurologic events (12%), cytopenias lasting more than 28 days (32%), infections (20%), and febrile neutropenia (14%). Three patients died from disease progression within 30 days after infusion. No deaths were attributed to tisagenlecleucel, cytokine release syndrome, or cerebral edema. No differences between response groups in tumor expression of CD19 or immune checkpoint-related proteins were found. CONCLUSIONS: In this international study of CAR T-cell therapy in relapsed or refractory diffuse large B-cell lymphoma in adults, high rates of durable responses were produced with the use of tisagenlecleucel. (Funded by Novartis; JULIET ClinicalTrials.gov number, NCT02445248 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These CAR T-cells were able to elicit complete responses (CR) in 32-67% of lymphoma patients and showed better CR rates in patients with leukemia (16-19).”
From Scalable Manufacturing of CAR T Cells for Cancer Immunotherapy (2021) · cites this paper as [17]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“First, most CAR T cell trials to date have used autologous peripheral blood and apheresis as the main cell sources for manufacturing (9-18,21,22).”
From Scalable Manufacturing of CAR T Cells for Cancer Immunotherapy (2021) · cites this paper as [17]
In the citing paper
“However, despite high initial response rates, complete and long-term remission is only achieved in up to 40% of patients13–16.”
From A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapy (2023) · cites this paper as [16]
In the citing paper
“Efficacy results seem similar in patients with LBCL treated with CD19 CAR T cells costimulated by 4-1BB instead of CD28, with or without fixing the ratio of CD4:CD8 cells.”
From Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma (2021) · cites this paper as [5]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
Neelapu, S. S., Locke, F. L., Bartlett, N. L., Lekakis, L. J., Miklos, D. B., Jacobson, C. A., Braunschweig, I., Oluwole, O. O., Siddiqi, T., Lin, Y., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707447 · Cited by 6,030
Self-citationTisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia
Maude, S. L., Laetsch, T. W., Buechner, J., Rives, S., Boyer, M., Bittencourt, H., Bader, P., Verneris, M. R., Stefanski, H. E., Myers, G. D., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1709866 · Cited by 5,735
Cheson, B. D., Fisher, R. I., Barrington, S. F., Cavalli, F., Schwartz, L. H., Zucca, E., & Lister, T. A. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.8800 · Cited by 5,715
Coiffier, B., Lepage, E., Brière, J., Herbrecht, R., Tilly, H., Bouabdallah, R., Morel, P., Van Den Neste, E., Salles, G., Gaulard, P., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011795 · Cited by 5,574
Self-citationChimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413
Current concepts in the diagnosis and management of cytokine release syndrome.
Lee, D. W., Gardner, R., Porter, D. L., Louis, C. U., Ahmed, N., Jensen, M., Grupp, S. A., & Mackall, C. L. (2014) · Blood · doi:10.1182/blood-2014-05-552729 · Cited by 2,806
Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas
Schuster, S. J., Svoboda, J., Chong, E. A., Nasta, S. D., Mato, A. R., Anak, Ö., Brogdon, J. L., Pruteanu-Malinici, I., Bhoj, V. G., Landsburg, D. J., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1708566 · Cited by 1,891
Self-citationOutcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study
Crump, M., Neelapu, S. S., Farooq, U., Neste, É. V. D., Kuruvilla, J. G., Westin, J. R., Link, B. K., Hay, A. E., Cerhan, J. R., Zhu, L., et al. (2017) · Blood · doi:10.1182/blood-2017-03-769620 · Cited by 1,755
Self-citationPorter, D. L., Hwang, W.-T., Frey, N. V., Lacey, S. F., Shaw, P. A., Loren, A. W., Bagg, A., Marcucci, K. T., Shen, A., Gonzalez, V., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aac5415 · Cited by 1,729
Gisselbrecht, C., Glaß, B., Mounier, N., Gill, D. S., Linch, D. C., Trněný, M., Bosly, A., Ketterer, N., Shpilberg, O., Hagberg, H., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.1618 · Cited by 1,639
Flagged first, then by citations
1 of the 29 references couldn’t be matched to a known paper.
Research works printed but not linked: 2
- Schuster SJ, Bishop MR, Tam CS, et al. Primary analysis of JULIET: a global, pivotal, phase 2 trial of CTL019 in adult patients with relapsed or refractory diffuse large B-cell lymphoma. Blood 2017;130:577-577. abstract.
- Maude SL, Grupp SA, Pulsipher MA, et al. Analysis of safety data from 2 multicenter trials of CTL019 in pediatric and young adult patients with relapsed/refractory (r/r) B-cell acute lymphoblastic leukemia (B-ALL). Haematologica 2017;102:197-198.
Cited by
Sorted by citations
Items 901–1,000 of 1,010
Canelo‐Vilaseca, M., Sabbah, M., Blasi, R. D., Cristinelli, C., Sureda, A. M., Caillat‐Zucman, S., & Thiéblemont, C. (2025) · Bone Marrow Transplantation · doi:10.1038/s41409-025-02539-9 · Cited by 39
“Only 2/8 patients who did not receive LD achieved a response [3, 36].”
Tracing the development of CAR-T cell design: from concept to next-generation platforms
Alsaieedi, A., & Zaher, K. A. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1615212 · Cited by 49
“Yescarta was initially approved based on a Phase 1/2 clinical trial called ZUMA-1, which involved patients with DLBCL, with a minority having primary mediastinal large B cell lymphoma (PMLBCL) (32).”
InfluentialJain, T., Sauter, C. S., Shah, G. L., Maloy, M., Chan, J. E., Scordo, M., Avecilla, S. T., Batlevi, Y., Dahi, P. B., Batlevi, C. L., et al. (2019) · Leukemia · doi:10.1038/s41375-019-0476-y · Cited by 37
Tully, S., Feng, Z. Z., Grindrod, K., McFarlane, T., Chan, K., & Wong, W. W. L. (2019) · JCO Clinical Cancer Informatics · doi:10.1200/cci.19.00086 · Cited by 37
Molecular background delineates outcome of double protein expressor diffuse large B-cell lymphoma
Meriranta, L., Pasanen, A., Alkodsi, A., Haukka, J. K., Karjalainen‐Lindsberg, M., & Leppä, S. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020001727 · Cited by 36
Dai, Q. G., Han, P., Qi, X., Li, F., Li, M., Fan, L., Zhang, H., Zhang, X., & Yang, X. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.539654 · Cited by 40
Danylesko, I., Shouval, R., Shem‐Tov, N., Yerushalmi, R., Jacoby, E., Besser, M. J., Shimoni, A., Davidson, T., Beider, K., Mevorach, D., et al. (2020) · Bone Marrow Transplantation · doi:10.1038/s41409-020-01156-y · Cited by 37
CAR‐T TREK through the lymphoma universe, to boldly go where no other therapy has gone before
Ghilardi, G., Brændstrup, P., Chong, E. A., Schuster, S. J., Svoboda, J., & Ruella, M. (2020) · British Journal of Haematology · doi:10.1111/bjh.17191 · Cited by 38
Self-citationLiu, R., Oluwole, O. O., Diakite, I., Botteman, M. F., Snider, J. T., & Locke, F. L. (2021) · Journal of Medical Economics · doi:10.1080/13696998.2021.1901721 · Cited by 37
Burns, E. A., Sanchez, C. G., Trachtenberg, B. H., Pingali, S. R., & Anand, K. (2021) · Diseases · doi:10.3390/diseases9010020 · Cited by 37
Fang, P., Gunther, J. R., Wu, S. Y., Dabaja, B. S., Nastoupil, L. J., Ahmed, S., Neelapu, S. S., & Pinnix, C. C. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.648655 · Cited by 38
Immunotherapy for Diffuse Large B-Cell Lymphoma: Current Landscape and Future Directions
Modi, D., Potugari, B. R., & Uberti, J. P. (2021) · Cancers · doi:10.3390/cancers13225827 · Cited by 38
Donor T cells for CAR T cell therapy
Tang, T. C. Y., Xu, N., Nordon, R. E., Haber, M., Micklethwaite, K. P., & Dolnikov, A. (2022) · Biomarker Research · doi:10.1186/s40364-022-00359-3 · Cited by 43
Perales, M., Kuruvilla, J. G., Snider, J. T., Vadgama, S., Blissett, R. S., Moustaid, F. E., Smith, N., Patel, A. R., & Johnston, P. B. (2022) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2022.08.010 · Cited by 37
Influence of TP53 Mutation on Survival of Diffuse Large B-Cell Lymphoma in the CAR T-Cell Era
Porpaczy, E. A., Wohlfarth, P., Königsbrügge, O., Rabitsch, W., Skrabs, C., Staber, P. B., Worel, N., Müllauer, L., Simonitsch‐Klupp, I., Kornauth, C., et al. (2021) · Cancers · doi:10.3390/cancers13225592 · Cited by 36
Neurological management and work-up of neurotoxicity associated with CAR T cell therapy
Möhn, N., Bonda, V., Grote-Levi, L. M., Panagiota, V., Fröhlich, T. C., Schultze-Florey, C. R., Wattjes, M. P., Beutel, G., Eder, M., David, S., et al. (2022) · Neurological Research and Practice · doi:10.1186/s42466-021-00166-5 · Cited by 36
A bibliometric analysis of diffuse large B-cell lymphoma research from 2001 to 2020
Jiang, J., Lv, W., & Chen, N. (2022) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2022.105565 · Cited by 36
Wada, F., Jo, T., Arai, Y., Kitawaki, T., Mizumoto, C., Kanda, J., Nishikori, M., Yamashita, K., Nagao, M., & Takaori‐Kondo, A. (2022) · Scientific Reports · doi:10.1038/s41598-022-23589-9 · Cited by 36
Complexities in comparing the impact of costimulatory domains on approved CD19 CAR functionality
Smith, R. M., & Shen, R. R. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04372-4 · Cited by 40
Reynolds, G. K., Sim, B., Spelman, T. D., Thomas, A., Longhitano, A., Anderson, M. A., Thursky, K., Slavin, M. A., & Teh, B. W. (2023) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2023.104134 · Cited by 36
Chen, X., Tan, B., Xing, H., Zhao, X., Ping, Y., Zhang, Z., Huang, J., Shi, X., Zhang, N., Lin, B., et al. (2024) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-023-03586-1 · Cited by 42
CAR-T-Cell-Based Cancer Immunotherapies: Potentials, Limitations, and Future Prospects
Choudhery, M. S., Arif, T., Mahmood, R., & Harris, D. T. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13113202 · Cited by 40
“This study indicates the significance of selecting target antigens that can reduce antigen escape and enhance antitumor response to prevent relapse [156].”
BackgroundCross-Talk Between Cancer and Its Cellular Environment—A Role in Cancer Progression
Turlej, E., Domaradzka, A., Radzka, J., Drulis‐Fajdasz, D., Kulbacka, J., & Gizak, A. (2025) · Cells · doi:10.3390/cells14060403 · Cited by 47
Emerging Therapies for the Treatment of Relapsed or Refractory Diffuse Large B Cell Lymphoma
Skrabek, P., Assouline, S. E., Christofides, A., Macdonald, D. B., Prica, A. A., Sangha, R. S., Matthews, B. A., & Sehn, L. H. (2019) · Current Oncology · doi:10.3747/co.26.5421 · Cited by 36
Zhang, Q., Orlando, E. J., Wang, H. Y., Bogusz, A. M., Liu, X., Lacey, S. F., Strauser, H. T., Nuñez-Cruz, S., Nejati, R., Zhang, P. J., et al. (2020) · Blood · doi:10.1182/blood.2020005123 · Cited by 36
Self-citationCircular RNA and tumor microenvironment
Song, H., Liu, Q., & Liao, Q. (2020) · Cancer Cell International · doi:10.1186/s12935-020-01301-z · Cited by 37
Is There Still a Role for Allogeneic Transplantation in the Management of Lymphoma?
Shah, N. N., & Hamadani, M. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.01447 · Cited by 36
Dimou, M., Papageorgiou, S. G., Stavroyianni, N., Katodritou, E., Tsirogianni, M., Kalpadakis, C. H., Banti, A., Arapaki, M. P., Iliakis, T., Bouzani, M., et al. (2021) · Hematological Oncology · doi:10.1002/hon.2842 · Cited by 36
Abramson, J. S., Siddiqi, T., Garcia, J., Dehner, C., Kim, Y., Nguyen, A., Snyder, S., McGarvey, N. H., Gitlin, M. D., Pelletier, C. L., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2020003531 · Cited by 36
Patrick, D. L., Powers, A., Jun, M. P., Kim, Y., Garcia, J., Dehner, C., & Maloney, D. G. (2021) · Blood Advances · doi:10.1182/bloodadvances.2020003503 · Cited by 36
CRISPR/Cas9 genome-edited universal CAR T cells in patients with relapsed/refractory lymphoma
Guo, Y., Tong, C., Su, L., Zhang, W., Jia, H., Liu, Y., Yang, Q., Wu, Z., Wang, Y., & Han, W. (2022) · Blood Advances · doi:10.1182/bloodadvances.2021006232 · Cited by 37
Caimi, P. F., Ardeshna, K. M., Reid, E. G., Ai, W. Z., Lunning, M. A., Zain, J. M., Solh, M., Kahl, B. S., & Hamadani, M. (2021) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2021.11.005 · Cited by 36
Resistance against anti-CD19 and anti-BCMA CAR T cells: Recent advances and coping strategies
Atilla, P. A., & Atilla, E. (2022) · Translational Oncology · doi:10.1016/j.tranon.2022.101459 · Cited by 37
Nanodrugs Targeting T Cells in Tumor Therapy
Haist, M., Mailänder, V., & Bros, M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.912594 · Cited by 36
Qu, C., Zou, R., Wang, P., Zhu, Q., Kang, L., Ping, N., Xia, F., Liu, H., Kong, D., Yu, L., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.969660 · Cited by 36
Caballero, A. C., Escribà-García, L., Álvarez‐Fernández, C., & Briones, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.904497 · Cited by 39
Nanomedicine for advanced cancer immunotherapy
Diep, Y. N., Kim, T. J., Cho, H., & Lee, L. P. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.10.004 · Cited by 35
Philippis, C. D., Mannina, D., Giordano, L., Costantini, E., Marcheselli, S., Mariotti, J., Sarina, B., Taurino, D., Santoro, A., & Bramanti, S. (2023) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2023.03.019 · Cited by 35
Bücklein, V., Perez, A. P., Rejeski, K., Iacoboni, G., Jurinović, V., Holtick, U., Penack, O., Kharboutli, S., Blumenberg, V., Ackermann, J., et al. (2023) · HemaSphere · doi:10.1097/hs9.0000000000000907 · Cited by 36
How I treat secondary CNS involvement by aggressive lymphomas
Alderuccio, J. P., Nayak, L., & Cwynarski, K. (2023) · Blood · doi:10.1182/blood.2023020168 · Cited by 35
Ghilardi, G., Paruzzo, L., Svoboda, J., Chong, E. A., Shestov, A. A., Chen, L., Cohen, I., Gabrielli, G., Nasta, S. D., Porazzi, P., et al. (2023) · Blood Advances · doi:10.1182/bloodadvances.2023011492 · Cited by 38
Self-citationChiappella, A., Casadei, B., Chiusolo, P., Rocco, A. D., Ljevar, S., Magni, M., Angelillo, P., Barbui, A. M., Cutini, I., Dodero, A., et al. (2024) · Leukemia · doi:10.1038/s41375-024-02213-x · Cited by 35
Ahmed, N., Sun, F., Teigland, C. L., Kilgore, K. M., Mohammadi, I., Chambers, J., Dieyi, C., Feng, C., Osborn, J., Fu, C. T., et al. (2024) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2024.04.017 · Cited by 35
Phase 1 study of CAR-37 T cells in patients with relapsed or refractory CD37+ lymphoid malignancies
Frigault, M. J., Graham, C., Berger, T. R., Ritchey, J., Horick, N., El-Jawahri, A. R., Scarfò, I., Schmidts, A., Haradhvala, N. J., Wehrli, M., et al. (2024) · Blood · doi:10.1182/blood.2024024104 · Cited by 37
Advancing CAR T-Cell Therapy in Solid Tumors: Current Landscape and Future Directions
Rafii, S., Mukherji, D., Komaranchath, A. S., Khalil, C., Iqbal, F., Abdelwahab, S. İ., Abyad, A. M., Abuhelwa, A. Y., Gandikota, L., & Al-Shamsi, H. O. (2025) · Cancers · doi:10.3390/cancers17172898 · Cited by 41
Zheng, L., Ren, L., Kouhi, A., Khawli, L. A., Hu, P., Kaslow, H. R., & Epstein, A. L. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3417 · Cited by 35
Chimeric Antigen Receptor T Cell Therapy Comes to Clinical Practice
Wall, D. A., & Krueger, J. (2020) · Current Oncology · doi:10.3747/co.27.5283 · Cited by 36
Fleischer, L. C., Becker, S. A., Ryan, R. E., Fedanov, A., Doering, C. B., & Spencer, H. T. (2020) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2020.06.003 · Cited by 36
Badbaran, A., Berger, C., Riecken, K., Kruchen, A., Geffken, M., Müller, I., Kröger, N. M., Ayuk, F. A., & Fehse, B. (2020) · Cancers · doi:10.3390/cancers12071970 · Cited by 35
Real-world adverse events associated with CAR T-cell therapy among adults age ≥ 65 years
Zettler, M. E., Feinberg, B. A., Phillips, E. G., Klink, A. J., Mehta, S., & Gajra, A. (2020) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2020.07.006 · Cited by 35
Novel Therapies for Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Harris, L. J., Patel, K., & Martin, M. G. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228553 · Cited by 36
Wang, S., Wang, L., Hu, J., Qian, W., Zhang, X., Hu, Y., Zhu, Q., Chen, B., Wu, D., Chang, C. H., et al. (2021) · 癌症：英文版 · doi:10.1002/cac2.12126 · Cited by 35
Mori, J., Adachi, K., Sakoda, Y., Sasaki, T., Goto, S., Matsumoto, H., Nagashima, Y., Matsuyama, H., & Tamada, K. (2021) · Cancer Science · doi:10.1111/cas.14835 · Cited by 37
Advances in Management for Older Adults With Hematologic Malignancies
Rosko, A. E., Córdoba, R., Abel, G. A., Artz, A. S., Loh, K. P., & Klepin, H. D. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.00242 · Cited by 35
Advances in chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma
Yin, Z., Zhang, Y., & Wang, X. (2021) · Biomarker Research · doi:10.1186/s40364-021-00309-5 · Cited by 36
Snyder, S., Albertson, T., Garcia, J., Gitlin, M. D., & Jun, M. P. (2021) · Advances in Therapy · doi:10.1007/s12325-021-01839-y · Cited by 35
Lamure, S., Laethem, F. V., de Verbizier, D., Lozano, C., Gehlkopf, E., Tudesq, J., Serrand, C., Benzaoui, M., Kanouni, T., Quintard, A., et al. (2021) · Cancers · doi:10.3390/cancers13174279 · Cited by 38
Strategies to Overcome Failures in T-Cell Immunotherapies by Targeting PI3K-δ and –γ
Chandrasekaran, S., Funk, C. R., Kleber, T. J., Paulos, C. M., Shanmugam, M., & Waller, E. K. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.718621 · Cited by 36
Self-citationProduction and Application of CAR T Cells: Current and Future Role of Europe
Vučinić, V., Quaiser, A., Lückemeier, P., Fricke, S., Platzbecker, U., & Koehl, U. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.713401 · Cited by 37
Imaging-based Toxicity and Response Pattern Assessment Following CAR T-Cell Therapy
Smith, D. A., Kikano, E. G., Tirumani, S. H., Lima, M. J. G. D., Caimi, P. F., & Ramaiya, N. H. (2021) · Radiology · doi:10.1148/radiol.2021210760 · Cited by 35
Targeted Drug Delivery and Theranostic Strategies in Malignant Lymphomas
Etrych, T., Braunová, A., Zogala, D., Lambert, L., Renešová, N., & Klener, P. (2022) · Cancers · doi:10.3390/cancers14030626 · Cited by 38
Development of anti-somatostatin receptors CAR T cells for treatment of neuroendocrine tumors
Mandriani, B., Pellè, E., Mannavola, F., Palazzo, A. J., Marsano, R. M., Ingravallo, G., Cazzato, G., Ramello, M. C., Porta, C., Strosberg, J., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-004854 · Cited by 41
Vijenthira, A., Kuruvilla, J. G., Crump, M., Jain, M. D., & Prica, A. A. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.22.00478 · Cited by 35
Diagnosis and Treatment of Primary Cutaneous B-Cell Lymphomas: State of the Art and Perspectives
Dumont, M., Battistella, M., Ram‐Wolff, C., Bagot, M., & de Masson, A. (2020) · Cancers · doi:10.3390/cancers12061497 · Cited by 35
T Cell Bispecific Antibodies: An Antibody-Based Delivery System for Inducing Antitumor Immunity
Kamakura, D., Asano, R., & Yasunaga, M. (2021) · Pharmaceuticals · doi:10.3390/ph14111172 · Cited by 37
Metelo, A. M., Jóźwik, A., Luong, L. A., Dominey-Foy, D., Graham, C., Attwood, C., Inam, S., Dunlop, A. S., Sanchez, K., Cuthill, K., et al. (2022) · Cancer Research Communications · doi:10.1158/2767-9764.crc-21-0157 · Cited by 35
How can Cytokine-induced killer cells overcome CAR-T cell limits
Cappuzzello, E., Vigolo, E., D’Accardio, G., Astori, G., Rosato, A., & Sommaggio, R. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1229540 · Cited by 34
Targeting the mevalonate or Wnt pathways to overcome CAR T-cell resistance in TP53-mutant AML cells
Mueller, J., Schimmer, R. R., Koch, C., Schneiter, F., Fullin, J., Lysenko, V., Pellegrino, C. E., Klemm, N., Russkamp, N. F., Myburgh, R., et al. (2024) · EMBO Molecular Medicine · doi:10.1038/s44321-024-00024-2 · Cited by 33
Satapathy, B. P., Sheoran, P., Yadav, R., Chettri, D., Sonowal, D., Dash, C. P., Dhaka, P., Uttam, V., Yadav, R., Jain, M., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1389971 · Cited by 41
Koeckerling, D., Reddy, R. K., Barker, J., Eichhorn, C., Divall, P., Howard, J. P., Korell, F., Schmitt, M. W., Dreger, P., Frey, N., et al. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.37222 · Cited by 35
Bachiller, M., Barceló-Genestar, N., Rodríguez-García, A., Alserawan, L., Dobaño‐López, C., Giménez-Alejandre, M., Castellsagué, J., Colell, S., Otero-Mateo, M., Antoñana-Vildosola, A., et al. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.11.028 · Cited by 35
Riedell, P. A., Grady, C. B., Nastoupil, L. J., Luna, A., Ahmed, N., Maziarz, R. T., Hu, M., Brower, J., Hwang, W., Schuster, S. J., et al. (2024) · Blood Advances · doi:10.1182/bloodadvances.2024014164 · Cited by 34
Self-citationCalabretta, E., & Carlo‐Stella, C. (2020) · Cells · doi:10.3390/cells9040802 · Cited by 36
Burkitt lymphoma: bridging the gap between advances in molecular biology and therapy
Zayac, A. S., & Olszewski, A. J. (2020) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2020.1747068 · Cited by 34
Bourbon, E., & Salles, G. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1800638 · Cited by 34
Self-citationCher, B. P., Gan, K. Y., Aziz, M. I. A., Lin, L., Hwang, W. Y. K., Poon, L. M., & Ng, K. (2020) · Journal of Medical Economics · doi:10.1080/13696998.2020.1808981 · Cited by 34
Yassine, F., Iqbal, M., Murthy, H. S., Kharfan‐Dabaja, M. A., & Chávez, J. C. (2020) · Current Research in Translational Medicine · doi:10.1016/j.retram.2020.05.005 · Cited by 34
CART Cell Toxicities: New Insight into Mechanisms and Management
Zahid, A., Siegler, E. L., & Kenderian, S. S. (2020) · Clinical Hematology International · doi:10.2991/chi.k.201108.001 · Cited by 37
Immunotherapies and immunomodulatory approaches in clinical trials - a mini review
Yatoo, M. I., Hamid, Z., RATHER, I. A., Nazir, Q. U. A., Bhat, R. A., Haq, A. U., Magray, S. N., Haq, Z. U., Sah, R., Tiwari, R., et al. (2021) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2020.1871295 · Cited by 36
Shao, M., Yu, Q., Teng, X., Guo, X., Wei, G., Xu, H., Cui, J., Chang, A. H., Hu, Y., & Huang, H. (2021) · Bone Marrow Transplantation · doi:10.1038/s41409-021-01226-9 · Cited by 37
Cardiovascular Toxicities of CAR T-cell Therapy
Patel, N. P., Doukas, P. G., Gordon, L. I., & Akhter, N. (2021) · Current Oncology Reports · doi:10.1007/s11912-021-01068-0 · Cited by 34
Meyer, J.-E., Loff, S., Dietrich, J., Spehr, J., Jiménez, G. J., Bonin, M. V., Ehninger, G., Cartellieri, M., & Ehninger, A. (2021) · OncoImmunology · doi:10.1080/2162402x.2021.1945804 · Cited by 35
Casadei, B., Argnani, L., Guadagnuolo, S., Pellegrini, C., Stefoni, V., Broccoli, A., Nanni, L., Morigi, A., Lolli, G., Guarino, M., et al. (2021) · Cancers · doi:10.3390/cancers13194789 · Cited by 34
Kambhampati, S., Saumoy, M., Schneider, Y., Serrao, S., Solaimani, P., Budde, L. E., Mei, M. G., Popplewell, L. L., Siddiqi, T., Zain, J. M., et al. (2022) · Blood · doi:10.1182/blood.2022016747 · Cited by 34
Radiotherapy as a means to increase the efficacy of T-cell therapy in solid tumors
Laurent, P.-A., Morel, D., Meziani, L., Depil, S., & Deutsch, É. (2022) · OncoImmunology · doi:10.1080/2162402x.2022.2158013 · Cited by 34
Glofitamab in relapsed/refractory diffuse large B‐cell lymphoma: Real‐world data
Ateşoğlu, E. B., Gülbaş, Z., Uzay, A., Özcan, M., Özkalemkaş, F., Dal, M. S., Kalyon, H., Akay, O. M., Devecı, B., Beköz, H. S., et al. (2023) · Hematological Oncology · doi:10.1002/hon.3174 · Cited by 34
Emole, J., Lawal, O., Lupak, O., Dias, A., Shune, L. O., & Yusuf, K. K. (2022) · Cancer Medicine · doi:10.1002/cam4.4797 · Cited by 33
Berger, S. C., Fehse, B., Akyüz, N., Geffken, M., Wolschke, C., Janson, D., Gagelmann, N., Luther, M., Wichmann, D., Frenzel, C., et al. (2022) · Haematologica · doi:10.3324/haematol.2022.281110 · Cited by 34
Ayuk, F. A., Gagelmann, N., von Tresckow, B., Wulf, G. G., Rejeski, K., Stelljes, M., Penack, O., Baldus, C. D., Kröger, N. M., Bethge, W. A., et al. (2023) · Blood Advances · doi:10.1182/bloodadvances.2023010336 · Cited by 33
Moreno-Cortes, E. F., Franco-Fuquen, P., García-Robledo, J. E., Forero-Forero, J. V., Booth, N. A., & Castro, J. E. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1200914 · Cited by 35
Kawai, A., Ishihara, M., Nakamura, T., Kitano, S., Iwata, S., Takada, K., Emori, M., Kato, K., Endo, M., Matsumoto, Y., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-1456 · Cited by 34
Fugere, T., Baltz, A., Mukherjee, A., Gaddam, M., Varma, A., Veeraputhiran, M. K., & Sanchez, C. G. (2023) · Cancers · doi:10.3390/cancers15215149 · Cited by 37
State of the Art in CAR-T Cell Therapy for Solid Tumors: Is There a Sweeter Future?
Amorós-Pérez, B., Rivas-Pardo, B., del Moral, M. G., Subiza, J. L., & Martı́nez-Naves, E. (2024) · Cells · doi:10.3390/cells13090725 · Cited by 34
“Tisa-cel received approval later for the treatment of r/r B-cell acute lymphoblastic leukemia (ALL) in children and young adults, and for the treatment of adults with DLBCL and follicular lymphoma (FL) [13,14].”
BackgroundHaydu, J. E., & Abramson, J. S. (2024) · Blood Advances · doi:10.1182/bloodadvances.2021004535 · Cited by 35
“For patients requiring 3L or later LBCL treatment, anti-CD19 CAR T-cells were approved beginning in 2017 (axi-cel, liso-cel, and tisa-cel), 4,8,14 making curative treatments available in multiply relapsed LBCL. Recent studies have also led to the approval of axi-cel and liso-cel for primary…”
BackgroundMethodTopp, M. S., Matasar, M. J., Allan, J. N., Ansell, S. M., Barnes, J. A., Arnason, J. E., Michot, J., Goldschmidt, N., O'Brien, S. M., Abadi, U., et al. (2024) · Blood · doi:10.1182/blood.2024027044 · Cited by 33
Metabolic reprogramming of CAR T cells: a new frontier in cancer immunotherapy
Frlic, T., & Pavlin, M. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1688995 · Cited by 38
“Correspondingly, higher frequencies of inhibitory receptors in leukapheresis T cells, peripheral or bone marrow T cells, or TME T cells correlate with worse responses in CAR T cell-treated patients (40, 195).”
Bouziana, S. D., & Bouzianas, D. G. (2020) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2020.04.003 · Cited by 33
CD19-directed CAR T-cell therapy in B-cell NHL
Kersten, M. J., Spanjaart, A. M., & Thiéblemont, C. (2020) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000668 · Cited by 33
Parking CAR T Cells in Tumours: Oncolytic Viruses as Valets or Vandals?
Evgin, L., & Vile, R. G. (2021) · Cancers · doi:10.3390/cancers13051106 · Cited by 34
Kelkar, A. H., Cliff, E. R. S., Jacobson, C. A., Abel, G. A., Dijk, S. W., Krijkamp, E. M., Redd, R., Zurko, J. C., Hamadani, M., Hunink, M. G. M., et al. (2023) · Annals of Internal Medicine · doi:10.7326/m22-2276 · Cited by 31
Metadata
- Authors
- Schuster, S. J., Bishop, M. R., Tam, C. S., Waller, E. K., Borchmann, P., McGuirk, J. P., Jäger, U., Jaglowski, S., Andreadis, C., Westin, J. R., Fleury, I., Bachanova, V., Foley, S. R., Ho, P. J., Mielke, S., Magenau, J. M., Holte, H., Pantano, S., Pacaud, L. B., Awasthi, R., Chu, J., Anak, Ö., Salles, G., & Maziarz, R. T.
- Affiliations
- The University of Sydney (AU)
- From the Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia (S.J.S.); the Hematopoietic Cellular Therapy Program, University of Chicago Medicine, Chicago (M.R.B.); Peter MacCallum Cancer Centre, St. Vincent’s Hospital and University of Melbourne, Melbourne, VIC (C.S.T.), and the Royal Prince Alfred Hospital and Department of Medicine, University of Sydney, Sydney (P.J.H.) — both in Australia; Winship Cancer Institute of Emory University, Bone Marrow and Stem Cell...
- Oslo University Hospital (NO)
- Novartis (Switzerland) (CH)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-01-03
- Volume
- 380
- Issue
- 1
- Pages
- 45-56
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2903062212
- Cited by
- 4,112
- References
- 29
- Citations by year
- 2026: 363 · 2025: 507 · 2024: 593 · 2023: 593 · 2022: 693 · 2021: 624 · 2020: 502 · 2019: 218
- FWCI
- 125.46
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Kölner Universitäts PublikationsServer (Universität zu Köln) (publishedVersion)
- Pure Amsterdam UMC (publishedVersion, cc-by)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- HAL (submittedVersion)
- Funders
- Novartis Pharmaceuticals Corporation
- Topics
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- tisagenlecleucel, CAR T-cell therapy, diffuse large B-cell lymphoma, relapsed/refractory lymphoma, CD19, autologous stem cell transplantation, cytokine release syndrome, neurological adverse events, relapse-free survival, complete response, immune checkpoint molecules
- MeSH terms
- Receptors, Chimeric Antigen, Progression-Free Survival, Adult, Aged, Female, Humans, Male, Middle Aged, Receptors, Antigen, T-Cell, Recurrence, Survival Analysis, Immunotherapy, Adoptive, Lymphoma, Large B-Cell, Diffuse, Young Adult, Neoplasm Grading
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
